Therapeutic activity of DCC‐2036, a novel tyrosine kinase inhibitor, against triple‐negative breast cancer patient‐derived xenografts by targeting AXL/MET
Yingying Shen(Sun Yat-sen University), Xuyu Zu(First Affiliated Hospital of University of South China)
Cited by 32
Related Papers
Inhibitory effect of the novel tyrosine kinase inhibitor DCC-2036 on triple-negative breast cancer stem cells through AXL-KLF5 positive feedback loop
|Cell Death and Disease|2022|36
Protein arginine N-methyltransferase�2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36
|Oncology Reports|2018|19
Negative feedback loop between ZBTB7A and TGF-β in breast cancer
|Oncology Letters|2017|13